Please assess the completion status of the following clinical trial:

Trial Title: Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients being attended by the mobile stroke unit with an acute ischemic stroke eligible for thrombolysis using standard clinical and CT criteria.~2. Patient's age is ≥18 years~3. Premorbid mRS \<4~Exclusion Criteria:~1. Intracranial hemorrhage (ICH) or other diagnosis (e.g. tumor) identified by CT on the MSU~2. Hypodensity in \>1/3 MCA territory or equivalent proportion of ACA or PCA territory on non-contrast CT on MSU~3. Pre-stroke mRS score of \> 3 (indicating significant previous disability)~4. Any terminal illness such that patient would not be expected to survive more than 1 year~5. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.~6. Pregnant women.~7. Rapidly improving symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous tenecteplase (TNK) (Type: ACTIVE_COMPARATOR): Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over \~10 seconds).
- Intravenous tissue plasminogen activator (tPA) (Type: ACTIVE_COMPARATOR): Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).